Quantumup
Oct 22, 10:43 AM
Cantor🏁
$CELC Overweight; PT
$140
$FTH $RLAY RHHBY AZN
Cantor said in its initiation report:
Celcuity is a commercial-stage oncology company that recently launched its first product, Revtorpyk (gedatolisib), a dual pan-PI3K/mTOR inhibitor, in second-line (2L) HR+/HER2- breast cancer.
The initial approval covers PIK3CA-wildtype patients (~60% of the 2L population), with an expected expansion into PIK3CA-mutant disease next year that would address the entire 2L population.
We view Celcuity as one of the few commercial-stage oncology companies with a credible path to multi-billion-dollar peak sales, offering investors an attractive launch driven growth story with additional strategic optionality.
